Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery

Completed · Phase 4

Conditions studied: Intraocular Lens Associated Postoperative Inflammation

In brief

To compare the relative effectiveness of the Imprimis Dropless™ (TriMoxiVanc) intraocular solution with the Less Drops™ topical formulation of PredMoxiKeterolac (given for the first week post op) followed by PredKeterolac (given for weeks 2 to 4 after surgery). The hypothesis is that the "dropless" regimen will be non-inferior to the "less drops" regimen in terms of post-operative IOP changes, post-operative healing, and visual quality.

Key facts

Study ID

NCT02819908

Run by

Eye Center of North Florida

People needed

25

Starts

2015-09-01

Expected to finish

2016-04-01

Last updated by the study team

2020-03-09

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Ocular criteria must be met in both eyes.
• Subject is undergoing bilateral cataract extraction or refractive lens exchange with intraocular lens implantation.
• Gender: Males and Females.
• Age: 21 or older.
• Willing and able to provide written informed consent for participation in the study.
• Willing and able to comply with scheduled visits and other study procedures.
• Willing and able to administer eye drops and record the times the drops were instilled.
• Scheduled to undergo standard cataract surgery or refractive lens exchange with topical anesthesia in both eyes within 6-15 days of each other.
• Potential postoperative best-corrected visual acuity of 20/30 or better.

You may not qualify if…

• If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.
• Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc.
• Presence of epiretinal membrane.
• Uncontrolled diabetes.
• Use of any systemic or topical drug known to interfere with visual performance.
• Contact lens use during the active treatment portion of the trial.
• Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
• History of chronic intraocular inflammation.
• History of retinal detachment.
• Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
• Previous refractive surgery.
• Anesthesia other than topical, oral or intravenous anesthesia (i.e. retrobulbar, general, etc).
• Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.
• Participation in (or current participation) any investigational drug or device trial within the previous 30 days prior to the start date of this trial.
• Intraocular conventional surgery within the past three months or intraocular laser surgery within one month.
• The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.
• Exclusion Criteria during surgery:
• If any of the following exclusion criteria are applicable to the study eye, the subject should not continue in the study.
• If full dose (0.2 cc) is not delivered into the vitreous through the zonules as evaluated by surgeon's direct visualization of the material in the posterior chamber with lack of material in the anterior chamber and an empty syringe.
• Significant vitreous loss.
• Significant anterior chamber hyphema.
• Uncontrollable intraocular pressure.
• Zonular or capsular rupture.
• Bag-sulcus, sulcus-sulcus or unknown placement of the haptics.
• Suturing of incision required at time of surgery.

Where it is running

• Eye Center of North Florida — Panama City, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.